Ignatius bean

Other Names

AguwasonBean of St. IgnatiusBittere FiebernussCabalongaDankkagiFaba bengalensisFaba IgnatiiFaba Sancti IgnatiiFava de Sant IgnasiFava di Santo IgnazioFève de Saint IgnaceFève igasuriqueHaba de San IgnacioHaba de Santo IgnazioIgasudIgnaciaIgnasbohnenIgnatiaIgnatia amaraIgnatiana philippicaIgnatiana philippinicaignatiibönaIgnatius-BohnenbaumIgnatius-BrechnussIgnatiusbohneIgnazbohnePepita de San IgnacioSaint Ignatius beanSemen IgnatiaeSt. Ignatius beanSt.-Ignaz-BohneStrychnos balansaeStrychnos beccariiStrychnos cuspidataStrychnos hainanensisStrychnos ignatiaStrychnos ignatiiStrychnos krabiensisStrychnos lanceolarisStrychnos maingayi var. fructuosaStrychnos maingayi var. fruticosaStrychnos novaStrychnos ovalifoliaStrychnos philippensisStrychnos pseudotieuteStrychnos tieuteUpas tieute

Synopsis

Ignatius Bean (Strychnos ignatii Berg.)

1. Identity: Botanical Classification, Nomenclature, and Morphology

1.1 Taxonomy and Scientific Names

Strychnos ignatii is a tree in the family Loganiaceae, native to the Philippines, particularly in Catbalogan, and parts of China. The plant is most widely known by the common name Saint Ignatius' bean, or simply Ignatius bean. Its synonym in older botanical and homeopathic literature is Ignatia amara — a name still used almost universally in homeopathic pharmacopeias and product labeling. Additional synonyms recorded in the literature include Ignatiana philippinica Lour. and Strychnos tieute.

The formal binomial Strychnos ignatii was established by Peter Jonas Bergius in 1778, preserving Kamel's eponymous tribute. Common names such as Saint Ignatius' bean and Ignatius bean directly echo this Jesuit nomenclature, while Philippine vernaculars include aguwason and dankkagi (Visayan), igasud (Cebuano), and katbalonga (Tagalog), reflecting the plant's cultural significance in traditional medicine before European contact. In Chinese medicine, the seeds are referred to as Lu Song Guo.

The epithet of the homeopathic name, amara, derives from the Latin word for "bitter." The Latin Strychnos means "a kind of nightshade," deriving from strychnos hypnóticás, the berries of Solanum dulcamara (bittersweet nightshade), which have a narcotic effect.

1.2 Plant Morphology

The St. Ignatius bean is a thornless, creeping plant that climbs to the highest treetops with its hooked, woody tendrils, which are compressed in the middle. The trunk can exceed 10 cm in diameter and has a smooth, reddish bark. The thin twigs with felt-like hair bear opposing elliptical or broadly ovate leaves up to 25 cm long. The tips of the leaves are shaped so as to allow water or dew to run off. The inconspicuous, greenish flowers are arranged in clustered umbels.

The plant produces a large spherical or ovoid fruit, measuring 10 centimetres or more in diameter, and containing about a dozen seeds embedded in a pulp, from which they have to be separated. The beans are of a dull, dark grey colour, and irregularly ovoid shape, measuring about 2.5 centimetres in length. Mutual pressure in the fruit has rendered them three, four, or five-sided and bluntly angular.

1.3 Geographic Distribution and Cultivation

The plant is native to a few islands in the Philippines and is cultivated in China, Indochina and India. The St. Ignatius bean tree flowers throughout the year. The vine prefers humid, well-drained soils with partial shade.

1.4 Common Preparations and Dosage Forms

In phytopharmaceutical and traditional practice, the seeds have been used in several forms. The tincture is added to mixtures or given as drops; in Continental practice a more concentrated preparation (1 in 2) is used under the name "Gouttes Amères de Baumé." The powdered drug may be administered in cachets or pills with other stomachics and digestives. The St. Ignatius bean yields its properties to water, but alcohol is its best solvent.

In modern homeopathic practice, the preparation differs fundamentally from crude botanical use. The homeopathic remedy Ignatia Amara is obtained from the tincture of the seeds of the fruit of the Strychnos ignatia plant — first dried and then pulverized — and from subsequent dilutions and dynamizations in a hydroalcoholic solution. The tincture is diluted in a ratio, often 1:10 (X scale) or 1:100 (C scale), and shaken vigorously at each stage. This process is repeated multiple times to achieve different potencies (e.g., 6X, 30C, 200C).

The drug is monographed in several official pharmacopeias. A.Vogel uses a homoeopathic dilution produced from the dried seeds in accordance with the current Homöopathisches Arzneibuch (HAB) (New Official German Homoeopathic Pharmacopeia). The U.S. DailyMed label for one commercial product lists the active ingredient as Ignatia amara 30C HPUS (0.44 mg), with less than 10⁻¹² mg strychnine alkaloids per pellet; the letters "HPUS" indicate that the components in this product are officially monographed in the Homeopathic Pharmacopoeia of the United States.

2. Historical and Traditional Use

2.1 Pre-European Philippines

Since the Spanish times, Strychnos ignatii has been known in the Philippines, used as an aphrodisiac and stimulant and also as a lethal poison. In the Philippines, locals refer to the plant as igasud. Due to their stomach- and intestine-strengthening effect, St. Ignatius beans were once used to "stimulate urine and wind." The crushed seeds were used to neutralise the effects of magical poisonings and love potions, and as a medication against fever and maw-worms (ascarids).

2.2 Jesuit Discovery and Introduction to Europe

The plant was first described by the Moravian (Czech) Jesuit working in the Philippines, brother Georg Kamel, who named its seeds "the beans of St. Ignatius," in honour of the founder of his religious order — Saint Ignatius of Loyola, the founder of Kamel's Jesuit missionary order. Kamel spent his life documenting plants and animals in the Philippines as part of his medical and pharmaceutical practice, and he discovered the healing properties of the St. Ignatius bean (Strychnos ignatii), a source of strychnine today. Kamel formally named the seeds Fabae Sancti Ignatii. The beans produced by Strychnos ignatii have been used to treat cholera. Strychnine was first isolated by Pierre-Joseph Pelletier in 1818 in Saint-Ignatius'-beans (S. ignatii), a woody vine of the Philippines.

The name "Bean of St. Ignatius" was applied to it by the Jesuits of that island, who found it highly esteemed by the natives for its medicinal properties. The seeds are very bitter but have no smell.

2.3 European Medical Tradition (18th–19th Centuries)

The drug was described as closely resembling Strychnos nux vomica in its medicinal properties. The seeds from which the drug is prepared are about an inch in length, convex on one side, facetted on the other; they are obtained from a medium-sized tree native to the Philippine Isles.

St. Ignatius beans have the medicinal properties of nux vomica seeds. They are used principally as a bitter and as a tonic. In 19th-century eclectics and pharmacopoeial tradition, the drug was characterized as affecting the nervous system, and was described as applicable to conditions involving what practitioners called "hysterical" presentations and nervous weakness.

The remedy presents the peculiarities of nux vomica to a great extent. In its therapeutic action it is prescribed under much the same conditions, but is a milder remedy. It seems to have less nerve-irritating properties and an efficient nerve-tonic influence. Ignatia is applicable if there is a tendency to mental disorder, with suffocative hysterical symptoms.

2.4 Introduction into Homeopathy

St. Ignatius bean was proved by Hahnemann and published in the third edition of his Materia Medica Pura. The information was also included in Allen's Encyclopedia. Although there is little scientific evidence regarding the medicinal use of ignatia, it was added to the Materia Medica (book of written descriptions of homeopathic medicines) in the early 1800s. Chinese doctors have used ignatia for emotional disorders such as depression and anxiety.

3. Key Constituents and Active Compounds

3.1 Alkaloid Content

The seeds contain from 2.5 to 3.0 per cent of alkaloid, about two-thirds of which consists of strychnine and one-third of brucine. They contain therefore rather more strychnine than nux vomica.

Pelletier and Caventou, in 1818, found the bean to contain the constituents of nux vomica only in different proportions. These chemists found 1.2 per cent of strychnine and little brucine. Later analyses produced differing results depending on the specimen batch and methodology. On analysis, the seeds have yielded the same constituents as the Strychnos nux vomica seeds; another analysis showed that these alkaloids were united as bases with igasuric acid, and yield also a volatile principle, extractives, gum, resin, fixed oil, and bassorin. They also contain about ten per cent of albuminoid matter.

The principal alkaloids are:

Strychnine — an indole alkaloid and the major toxic constituent, comprising the majority of the total alkaloid fraction.
Brucine (2,3-dimethoxystrychnidin-10-one) — a weak alkaline indole alkaloid, white crystalline powder with molecular formula C₂₃H₂₆N₂O₄ and a molecular weight of 394.

Chromatographic analysis has confirmed both principal alkaloids in the homeopathic mother tincture. Superimposed UV spectra of brucine standard show λ-max at 306 nm, whereas superimposed UV spectra of strychnine standard show λ-max at 259 nm, which matches the λ-max shown by Ignatia Amara mother tincture — one at 260 nm and one at 306 nm. It is therefore evident from the chromatogram that Ignatia Amara homoeopathic mother tincture contains both brucine and strychnine.

3.2 Additional Secondary Metabolites

Ignatia Amara contains several chemical constituents, including indole alkaloids such as strychnine, brucine, and ignatine, which contribute to its pharmacological effects. Beyond alkaloids, the seeds contain:

Flavonoids, including quercetin, which has antioxidant properties.
Tannins with astringent properties; essential oils with potential calming or stimulating effects; and glycosides with diverse physiological effects that contribute to the plant's therapeutic profile.
Igasuric acid — a substance identified by Höhn as an iron-greening tannic acid — which was observed by Pelletier and Caventou to occur in natural combination with the alkaloids.

4. Mechanisms of Action

4.1 Strychnine: Glycine Receptor Antagonism

Strychnine is a neurotoxin which acts as an antagonist of glycine and acetylcholine receptors. It primarily affects the motor nerve fibers in the spinal cord which control muscle contraction.

The molecular basis of strychnine's CNS excitatory action is well established in the neuropharmacological literature. Glycine acts primarily as an agonist of the glycine receptor, which is a ligand-gated chloride channel in neurons located in the spinal cord and in the brain. This chloride channel allows the negatively charged chloride ions into the neuron, causing a hyperpolarization which pushes the membrane potential further from threshold. Strychnine is an antagonist of glycine; it binds noncovalently to the same receptor, preventing the inhibitory effects of glycine on the postsynaptic neuron.

Strychnine is a potent competitive glycine receptor (GlyR) antagonist that locks the receptor in a closed state, precluding chloride permeation. Strychnine acts at the intersubunit, canonical neurotransmitter site. Strychnine acts as a selective competitive antagonist to block the inhibitory effects of glycine at the glycine receptors. Studies suggest that strychnine and glycine interact with the same receptor (a ligand-gated chloride channel) but at different sites. There is also evidence of an increase in brain levels of glutamic acid, an amino acid that acts as a transmitter for excitatory nerve impulses that excite muscle contraction. The result of these effects is that skeletal muscles become hyperexcitable.

The strychnine-sensitive glycine receptor (GlyR) mediates inhibitory synaptic transmission in the spinal cord and brainstem and is linked to neurological disorders including autism and hyperekplexia.

4.2 Neurological Effects at the Spinal Level

Ignatius bean acts specially on the medulla oblongata and spinal nervous system, giving rise to tetanic convulsions. The entire nervous system gets affected, making the system sensitive — there is intense acuteness of the nerves of sensation and of special senses and increased susceptibility to external impressions, mental and physical. If we were to correlate this with the pharmacological action of strychnine and brucine, all the actions of Ignatia can aptly be assigned to the pharmacological action of these two active principles.

In the early effects of exposure, there is nervous system hypersensitivity (particularly of vision and hearing) and excitability. Toxic effects from the ingestion of this raw material include restlessness, anxiety, dizziness, hyperreflexia, twitching, spasms, convulsions, difficult breathing, and death.

4.3 Brucine: Pharmacological Mechanisms

Modern pharmacology studies and clinical practice demonstrate that brucine possesses wide pharmacological activities, such as anti-tumor, anti-inflammatory, analgesic, and effects on the cardiovascular system and nervous system. However, its central nervous system toxicity severely limits its clinical application.

Brucine demonstrates multi-target pharmacological effects, including induction of apoptosis, inhibition of proliferation and angiogenesis in cancer models, suppression of inflammatory cytokines via NF-κB and MAPK pathways, and modulation of nociceptive pathways.

Brucine is an alkaloid resembling strychnine but is much less potent than strychnine. Brucine causes paralysis of the peripheral nerve endings and produces violent convulsions.

5. Scientific Evidence by Area of Use

5.1 Anxiety and Mood Disorders (Homeopathic Use)

Evidence level: Preliminary; animal and very limited clinical data only.

The most studied application of Ignatius bean — as a homeopathic preparation (Ignatia amara) — concerns emotional and mood-related presentations. Ignatia is one of the homeopathic remedies most commonly used on patients with anxiety symptoms, depression, manic episodes, emotive urination and diarrhoea, as well as hyperaesthesia and hypersensitivity to emotions.

A key pre-clinical investigation used validated animal behavioral models. Ignatia amara (Ignatia), a remedy made from Strychnos ignatii seeds, is used for anxiety-related symptoms, but consistent evidence of its activity in reproducible experimental models is lacking. An investigation was performed in order to assess on mice, by means of emotional response models, the activity of homeopathic Ignatia dilutions/dynamizations. Groups of 8 mice of the CD1 albino strain were treated intraperitoneally for 9 days with 0.3 ml of five centesimal (C) dilutions/dynamizations of Ignatia (4C, 5C, 7C, 9C and 30C). The conclusion was that homeopathic Ignatia dilutions/dynamizations (peak at 9C) modify some emotion-related symptoms in laboratory mice without affecting locomotion.

The relevance of this pre-clinical finding to humans remains uncertain. Anxiety and depression are among the symptoms most frequently reported by patients seeking complementary or alternative medical treatments. In homeopathy, the opposite has been true compared to conventional drugs: trials on humans have only recently been followed up with tests on animals. No large-scale, double-blind, placebo-controlled randomized clinical trials in humans specifically for anxiety or grief using Ignatia amara have been identified in peer-reviewed indexed literature.

5.2 Oral Lichen Planus

Evidence level: Single small randomized controlled trial; results are preliminary.

A randomised single-blind trial involving 30 patients treated with homeopathic Ignatia amara for histologically confirmed oral lichen planus, where treatment endpoints included mean lesion size and pain scores, found a significantly more positive effect on these endpoints after use of Ignatia amara compared with placebo. Ignatia amara in 30C attenuation was evaluated for its effectiveness in treating oral lichen planus in a randomized controlled trial of 30 human subjects. The study suggests that the medicine was effective in reducing the average size of lesions and pain level after four months.

A small case series (n = 4) studying the effects of various homeopathic agents (Ignatia amara, Aurum metallicum, Lycopodium and Carcinosinum) on generalised lichen planus, with or without mucosal involvement, of varying disease durations, suggested homeopathy achieved sustained remission in all cases. These data are very limited in sample size, lack blinding in the case series, and do not constitute sufficient evidence to draw general conclusions.

5.3 Brucine: Anti-inflammatory and Analgesic Activity

Evidence level: Pre-clinical (animal and cell-based) only; no confirmed human clinical trials.

It has been demonstrated that brucine possessed analgesic and anti-inflammatory activity in a dose-dependent manner. Cytotoxicities of brucine against various tumor cells including skin tumor cells were also compared in vitro. Brucine is usually used as an anti-inflammatory and analgesic drug to relieve arthritis and traumatic pain.

The anti-inflammatory and analgesic effect of brucine has been evaluated by various nano-formulations such as liposomes, microspheres, hydrogels, nanoemulgel, and nanoemulsions, which have successfully achieved efficacy and reduced toxicity. The results of transdermal administration studies indicated that transdermal administration might be beneficial for the sustained efficacy and reduced toxicity of brucine.

5.4 Brucine: Anticancer Activity

Evidence level: Pre-clinical (cell lines and animal models) only; no human clinical trials.

In vitro and in vivo studies have demonstrated that brucine is able to inhibit the proliferation of liver cancer cells and growth of animal tumors, and may be a promising anticancer drug. However, high toxicity, poor water solubility, short half-life, narrow therapeutic window, and similar therapeutic and toxic doses limit its clinical application in the treatment of malignant tumors.

Recent years, brucine has displayed anti-tumor effects on various tumors. For hepatocellular carcinoma, brucine could inhibit the proliferation of HepG2 cells through regulating calcium concentration and depolarization of mitochondria. In bone metastasis nude mice model of breast cancer, brucine might inhibit tumor angiogenesis, growth, and bone metastasis by down-regulating vascular endothelial growth factor (VEGF) expression. Brucine could also inhibit the growth and migration of colorectal cancer cells LoVo by regulating Wnt/β-catenin signaling pathway.

A 2021 PubMed-indexed study examined brucine in cervical cancer cell lines. Brucine inhibited inflammation, cell proliferation, and promoted apoptotic cell death and reduced the mitochondrial potential. ELISA and real-time PCR determined that brucine downregulated inflammatory markers (TNF-α, NF-κB, IL-6, COX-2), cell proliferation markers (Cyclin D1), and modulated the PI3K/AKT/mTOR pathway. All of these results are in vitro and do not constitute clinical evidence of anti-cancer efficacy in humans.

There are no properly designed clinical trials and mechanistic data on toxicology that relate the molecular pathways to the adverse effects observed in humans.

5.5 Tonic and Stomachic Uses (Historical Pharmacology)

Evidence level: Historical/traditional only; no controlled clinical evidence.

Ignatia amara must have a similar action to nux vomica, and it has in fact been proposed as a substitute for that drug. In practice, however, it seems to differ somewhat from nux vomica. The action and uses of ignatia are very similar to those of nux vomica, but more energetic. 19th-century practitioners used the drug as a bitter tonic for digestive weakness, a practice grounded in the bitter alkaloid content stimulating gastric secretion — a mechanism not specifically studied for S. ignatii in modern controlled trials.

5.6 Overall Evidence Assessment

A comprehensive review of the literature on homeopathy evaluated its effectiveness in clinical practice. While there is evidence of clinical benefits of homeopathy, its formal application requires more rigorous randomised controlled trials. The FDA disclaimer on US-marketed Ignatia amara products states that homeopathic products have not been evaluated by the Food and Drug Administration for safety or efficacy, and that the FDA is not aware of scientific evidence to support homeopathy as effective. Ignatia was commonly used in the 1800s but has not been studied in modern scientific trials at a scale sufficient to draw conclusions about efficacy for any indication.

6. Body Systems and Health Areas Associated with Ignatius Bean

The following systems are historically or scientifically associated with S. ignatii and its constituents:

Central and Peripheral Nervous System: The dominant pharmacological target of both strychnine (spinal cord glycine receptors) and brucine (peripheral nerve endings). Ignatius bean acts specially on the medulla oblongata and the spinal nervous system.
Musculoskeletal System: Strychnine-induced glycine receptor blockade leads to skeletal muscle hyperexcitability, historically proposed (in sub-toxic doses) as a muscle tonic. At toxic doses, it causes tetanic convulsions.
Gastrointestinal System: Due to their stomach- and intestine-strengthening effect, St. Ignatius beans were once used to stimulate urine and wind. Traditional use as a bitter digestive stimulant is recorded across multiple sources.
Emotional and Psychological Domain: In homeopathic tradition, Ignatia amara 30C is indicated for temporarily relieving symptoms associated with occasional nervous tension such as hypersensitivity, apprehension, irritability, grief or sadness, moodiness, lump in throat, and nervous yawning.
Immune and Oncological (Experimental): Brucine has shown preclinical activity against cancer cell lines, but no approved clinical use exists.
Dermatological: Limited homeopathic study data exist for oral lichen planus, as described above.

7. Dosage Forms and Dosages Reported in Sources

The following dosage information is drawn directly from historical pharmacopoeial sources and identified studies, and applies to different eras and contexts of use:

Specific Medicine Ignatia (19th-century eclectic practice): Dose, from one-sixth to one-half minim; prescribed from five to fifteen drops in four ounces of water, a teaspoonful every two hours.
Fluid Extract of Ignatia (19th-century eclectic practice): Fluid extract of Ignatia; dose, from one to ten minims.
Tincture of Ignatia (19th-century eclectic practice): Tincture of Ignatia; dose, from five to twelve minims.
Homeopathic potency in the oral lichen planus RCT: Ignatia amara in 30C attenuation was evaluated for its effectiveness in treating oral lichen planus in a randomized controlled trial of 30 human subjects.
Homeopathic potency in the mouse behavioural study: Groups of 8 mice were treated intraperitoneally for 9 days with 0.3 ml of five centesimal (C) dilutions/dynamizations of Ignatia (4C, 5C, 7C, 9C and 30C).
Commercial homeopathic pellet (US DailyMed): Active ingredient: Ignatia amara 30C HPUS (0.44 mg) — less than 10⁻¹² mg strychnine alkaloids per pellet.
Brucine transdermal doses (pre-clinical mouse study): Three transdermal doses (10, 20, and 40 mg/kg) were administered to mice to evaluate pharmacological activity.

It should be noted that the crude seed contains 2.5–3.0% total alkaloid. Given the acute lethal dose of strychnine in humans, no safe therapeutic dose of the raw or crude seed or extract has been established in modern clinical literature, and 19th-century dosage forms cited above should be understood in their historical context only.

8. Safety, Toxicity, and Drug Interactions

8.1 Acute Toxicity of Strychnine

Strychnine is very toxic to humans (minimum lethal oral dose in adults is 30–120 mg) and many other animals (oral LD50 = 16 mg/kg in rats, 2 mg/kg in mice), and poisoning by inhalation, swallowing, or absorption through eyes or mouth can be fatal. The usual fatal dose is 60–100 mg strychnine, and is fatal after a period of 1–2 hours, though lethal doses vary depending on the individual.

Strychnine is a bitter indole alkaloid obtained mainly from the seeds of Strychnos nux-vomica and Strychnos ignatii. All parts of S. nux-vomica and S. ignatii may contain strychnine and brucine (dimethoxystrychnine), a related but less potent alkaloid.

8.2 Clinical Signs of Strychnine Poisoning

Due to the strychnine content, taking Ignatius bean by mouth may cause restlessness, anxiety, heightened sense perception, enhanced reflexes, equilibrium disorders, painful back and neck stiffness, twitching, spasms of jaw and neck muscles, convulsions triggered by visual or touch stimulation with possible opisthotonos (rigid muscle contraction), extreme muscle tension, hyperthermia, seizures, metabolic acidosis, fatal cardiac arrest, and rhabdomyolysis. The proximate cause of death in strychnine poisoning can be cardiac arrest, respiratory failure, multiple organ failure, or brain damage.

Unintentional poisoning has been reported following ingestion of traditional herbal remedies, including the Chinese preparation maqianzi — the dried ripe seed of Strychnos nux-vomica containing strychnine and brucine.

8.3 Toxicity of Brucine

Brucine is about one-eighth as toxic as strychnine in humans. The probable lethal dose for strychnine is estimated between 30–120 mg, whereas for brucine, it is around 1 gram. The therapeutic window is quite narrow, and the reported lethal dose 50% (LD50) value of brucine was 50.10 mg/kg (in animal studies), which severely limits its clinical application. Brucine has toxic effects on the nervous system, immune system, urinary system, and digestive system. Serious central nervous system toxicity is the main obstacle to brucine's clinical application.

8.4 No Available Antidote

There is no antidote for strychnine poisoning. Management of strychnine poisoning focuses on supportive care, with emphasis on rapid control of muscle hyperactivity to prevent metabolic and respiratory complications. Patients with significant poisoning should receive intensive care, ideally under guidance from a regional poison control center or medical toxicologist. Gastrointestinal decontamination with activated charcoal (1 g/kg) may be considered within the first few hours of ingestion. Benzodiazepines are the preferred first-line medications for strychnine-induced muscular convulsions.

8.5 Regulatory Status

The U.S. Food and Drug Administration (FDA) banned strychnine from non-regulated products in 1989. The US Food and Drug Administration (FDA) banned strychnine from nonprescription drug products in 1989. For occupational exposures to strychnine, the Occupational Safety and Health Administration and the National Institute for Occupational Safety and Health have set exposure limits at 0.15 mg/m³ over an 8-hour work day.

8.6 Contraindications and Special Populations

Ignatia should be avoided in patients with liver disease since strychnine accumulates in individuals with liver damage and can cause further damage. Ignatia may also cause myoglobinuric renal failure, and caution is advised in patients with compromised kidney function. Ignatia is not recommended in pregnant or breastfeeding women due to toxic effects.

Toxic effects from the ingestion of this raw material include restlessness, anxiety, dizziness, hyperreflexia, twitching, spasms, convulsions, difficult breathing, and death. Even at low doses, chronic exposure can be fatal.

8.7 Drug Interactions

Ignatia amara may interact with and disrupt the functioning of some prescription medications, such as antidepressants, anti-anxiety drugs, and sedatives. From a mechanistic standpoint, the glycine receptor antagonism of strychnine may theoretically interfere with CNS-active drugs that modulate inhibitory neurotransmission, although specific pharmacokinetic interaction studies with S. ignatii crude preparations are not available in the peer-reviewed literature.

In homeopathic dilutions such as 30C (as commonly marketed), less than 10⁻¹² mg of strychnine alkaloids per pellet is present — a quantity far below pharmacologically active or toxic thresholds. Accordingly, the toxicological concerns cited above apply primarily to preparations containing measurable alkaloid concentrations (crude extracts, mother tinctures, low-potency preparations).

References

Health Conditions

Health conditions that Ignatius bean may help support.

No conditions available.

Body Systems

Body systems that Ignatius bean may help support.

No body systems available.